The GPhC has issued a statement to give clarity to pharmacy professionals and patients and the public on the supply of the drug Avastin off licence for wet age-related macular degeneration (wet AMD). This follows the dismissal in the High Court of a judicial review brought by two pharmaceutical companies against 12 Clinical Commissioning Groups on 21 September 2018.
The full judgment is available to read on their website.
Our pharmacyregulation.org website will not be available this evening from 7pm to 9pm due to essential maintenance. We are sorry for any inconvenience this may cause.
Please note this will not affect our other websites: mygphc.org or mygphcpharmacy.org.
The GPhC Council agreed to begin a consultation in the coming month on an increase to some of its fees for 2019-20 at its meeting on 11 October 2018. In the consultation, the GPhC will propose to increase the entry and yearly renewal fe...
Our next council meeting takes place on Thursday 11 October 2018. Read the agenda and papers for the meeting.
You can follow the meeting live from our twitter account.
The GPhC welcomes the Professional Standards Authority’s (PSA) annual review of its performance for 2017/18, which found for the third consecutive year that it has met all the PSA’s standards for good regulation.
The review includes an analysis of the GPhC’s performance including;
Recent Comments